Alerts will be sent to your verified email
Verify EmailERIS
Eris Lifesciences
|
Torrent Pharma
|
Astrazeneca Pharma I
|
|
---|---|---|---|
Operational Metrics
|
|||
Pharmaceutical Sector
|
|||
Domestic Sales Growth - YoY
|
8.7 % | 11.1 % | 18.6 % |
R&D as a % of Total Sales
|
0.0 | 5.0 % | 0.0 |
Financials
|
|||
5 yr Average ROE
|
21.87 % | 17.02 % | 17.46 % |
5yr average Equity Multiplier
|
1.23 | 2.5 | 1.97 |
5yr Average Asset Turnover Ratio
|
0.65 | 0.61 | 0.99 |
5yr Avg Net Profit Margin
|
27.87 % | 11.26 % | 9.04 % |
Price to Book
|
5.04 | 13.58 | 20.67 |
P/E
|
31.42 | 60.95 | 97.19 |
5yr Avg Cash Conversion Cycle
|
-52.94 Days | -151.22 Days | -120.04 Days |
Inventory Days
|
26.19 Days | 54.43 Days | 63.93 Days |
Days Receivable
|
46.91 Days | 39.91 Days | 35.03 Days |
Days Payable
|
168.01 Days | 337.02 Days | 229.92 Days |
5yr Average Interest Coverage Ratio
|
96.59 | 4.68 | 104.17 |
5yr Avg ROCE
|
24.86 % | 21.27 % | 23.44 % |
5yr Avg Operating Profit Margin
|
36.16 % | 29.61 % | 15.59 % |
5 yr average Debt to Equity
|
0.11 | 0.97 | 0.0 |
5yr CAGR Net Profit
|
5.62 % | 23.34 % | 12.77 % |
5yr Average Return on Assets
|
18.27 % | 6.93 % | 8.84 % |
Shareholdings
|
|||
Promoter Holding
|
54.9 % | 71.25 % | 75.0 % |
Share Pledged by Promoters
|
18.51 % | 0.0 | 0.0 |
Change in Promoter Holding (3 Yrs)
|
0.77 % | 0.0 | 0.0 |
Change in Mutual Fund Holding (3 Yrs)
|
5.69 % | -2.01 % | 2.92 % |
Eris Lifesciences
|
Torrent Pharma
|
Astrazeneca Pharma I
|
|
---|---|---|---|
Product Wise Break-Up
|
Product Wise Break-Up
|
Product Wise Break-Up
|
Product Wise Break-Up
|
Entity Wise Breakup
|
Entity Wise Breakup
|
-
|
-
|
EBITDA - Entity Wise
|
EBITDA - Entity Wise
|
-
|
-
|
Therapeutic Area Wise Break-Up - Domestic
|
Therapeutic Area Wise Break-Up - Domestic
|
-
|
-
|
Location Wise Break-Up
|
Location Wise Break-Up
|
Location Wise Break-Up
|
Location Wise Break-Up
|
Acute vs Chronic
|
Acute vs Chronic
|
Acute vs Chronic
|
-
|